Gideon Akuamoah Wiafe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Gideon Akuamoah Wiafe has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Akua Afriyie Karikari
Department of Biomedical Sciences, School of Allied Health Sciences, University of Cape Coast, Cape Coast, Ghana
2 shared publications - Daniel Lawer Egbenya
Department of Physiology, School of Medical Sciences, College of Health and Allied Sciences University of Cape Coast Cape Coast Ghana
2 shared publications - Du-Bois Asante
Department of Forensic Sciences, School of Biological Sciences, University of Cape Coast, Cape Coast, Ghana
2 shared publications - Francis Tanam Djankpa
Department of Physiology, School of Medical Sciences, College of Health and Allied Sciences, University of Cape Coast, Cape Coast, Ghana
2 shared publications - Abdala Mumuni Ussif
Department of Forensic Sciences, School of Biological Sciences, University of Cape Coast, Cape Coast, Ghana
1 shared publication Abdala Ussif
Department of Forensic Sciences University of Cape Coast Cape Coast Ghana
1 shared publication
Latest Publications
- Open Access
- 27 May 2026
- Published by F1000 Research Ltd in Wellcome Open Research
- Vol. 11, 311
Case Report: Resolving a Diagnostic Odyssey in Spinal Muscular Atrophy Using HiFi Long-Read Whole Genome Sequencing
Compound heterozygous SMN1 genotypes account for approximately 5% of spinal muscular atrophy (SMA) cases but are difficult to detect using conventional short-read sequencing due to near-identical homology between SMN1 and its paralog SMN2. We describe a patient with a decade-long diagnostic odyssey in whom whole exome and short-read whole genome sequencing failed to establish a diagnosis, despite a single SMN1 copy having been detected and dismissed as carrier status. The patient presented in childhood with progressive proximal limb weakness, tongue atrophy with fasciculations and electrophysiological evidence of chronic neurogenic disease. High-fidelity long-read whole genome sequencing resolved the SMN locus unambiguously, identifying a compound heterozygous genotype comprising an SMN1 gene deletion and a likely pathogenic missense variant (c.347 T>C; p.Ile116Thr) on the remaining allele, confirming SMA type 3. This case illustrates how long-read sequencing can resolve paralogous genomic regions intractable to short-read approaches, and highlights that a single detected SMN1 copy in a patient with a compatible phenotype warrants evaluation for a second sequence-level variant.
- 27 May 2026
- Published by F1000 Research Ltd in Wellcome Open Research
- Vol. 11, 311
Open AccessCase Report: Resolving a Diagnostic Odyssey in Spinal Muscular Atrophy Using HiFi Long-Read Whole Genome Sequencing
Compound heterozygous SMN1 genotypes account for approximately 5% of spinal muscular atrophy (SMA) cases but are difficult to detect using conventional short-read sequencing due to near-identical homology between SMN1 and its paralog SMN2. We describe a patient with a decade-long diagnostic odyssey in whom whole exome and short-read whole genome sequencing failed to establish a diagnosis, despite a single SMN1 copy having been detected and dismissed as carrier status. The patient presented in childhood with progressive proximal limb weakness, tongue atrophy with fasciculations and electrophysiological evidence of chronic neurogenic disease. High-fidelity long-read whole genome sequencing resolved the SMN locus unambiguously, identifying a compound heterozygous genotype comprising an SMN1 gene deletion and a likely pathogenic missense variant (c.347 T>C; p.Ile116Thr) on the remaining allele, confirming SMA type 3. This case illustrates how long-read sequencing can resolve paralogous genomic regions intractable to short-read approaches, and highlights that a single detected SMN1 copy in a patient with a compatible phenotype warrants evaluation for a second sequence-level variant.
- Open Access
- 8 July 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 24442
RareInsight simplifies the communication of genetic results for rare disease patients
Following a confirmed genetic diagnosis, rare disease patients and their families encounter significant challenges in accessing diagnostic information and support. Patients and non-specialists are increasingly expected to interpret and share test results; however, existing standards are primarily designed for specialists. These standards fail to address the needs of resource-limited populations where low genomic literacy hampers accurate dissemination of genetic results. This research introduces RareInsight, an open-source, interactive dashboard designed to enhance the accessibility, comprehension, and collaboration of genetic data among patients, caregivers, clinicians, and researchers. Developed using shinydashboard, RareInsight was evaluated using whole exome sequencing data from skeletal dysplasia patients. It allows users to input and view Variant Call Format files and includes a searchable ClinVar variant table with filtering options, providing access to multiple resources based on search terms. RareInsight aims to simplify the dissemination of complex genetic information beyond the clinical setting. This dashboard serves as a pilot study demonstrating the potential of patient-centered interactive dashboards for the rare disease community.
- 8 July 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 24442
Open AccessRareInsight simplifies the communication of genetic results for rare disease patients
Following a confirmed genetic diagnosis, rare disease patients and their families encounter significant challenges in accessing diagnostic information and support. Patients and non-specialists are increasingly expected to interpret and share test results; however, existing standards are primarily designed for specialists. These standards fail to address the needs of resource-limited populations where low genomic literacy hampers accurate dissemination of genetic results. This research introduces RareInsight, an open-source, interactive dashboard designed to enhance the accessibility, comprehension, and collaboration of genetic data among patients, caregivers, clinicians, and researchers. Developed using shinydashboard, RareInsight was evaluated using whole exome sequencing data from skeletal dysplasia patients. It allows users to input and view Variant Call Format files and includes a searchable ClinVar variant table with filtering options, providing access to multiple resources based on search terms. RareInsight aims to simplify the dissemination of complex genetic information beyond the clinical setting. This dashboard serves as a pilot study demonstrating the potential of patient-centered interactive dashboards for the rare disease community.
- Open Access
- 22 November 2023
- Published by Wiley in Journal of Diabetes Research
- Vol. 2023, 1-12
Therapeutic Benefit of Vernonia amygdalina in the Treatment of Diabetes and Its Associated Complications in Preclinical Studies
Diabetes mellitus (DM), a complex heterogeneous metabolic disorder characterized by a defect in the function of insulin, is on the rapid rise globally. Sustained hyperglycemia which is a major sign of DM is linked to the generation of reactive oxygen species which promotes adverse complications of the disorder. Traditional herbal treatment of DM is a common practice in Africa and other tropical parts of the world. Vernonia amygdalina (VA), one of the highly researched species in the Asteraceae family, has proven to possess potent antidiabetic properties. Several phytochemicals identified in multiple extracts from VA are purported to be responsible for the antidiabetic potential of the plant. In this review, we discuss the therapeutic potential of VA in diabetes and its associated complications. We appraise the current evidence and further suggest potential areas that could be effectively exploited in future VA research on diabetes.
- 22 November 2023
- Published by Wiley in Journal of Diabetes Research
- Vol. 2023, 1-12
Open AccessTherapeutic Benefit of Vernonia amygdalina in the Treatment of Diabetes and Its Associated Complications in Preclinical Studies
Diabetes mellitus (DM), a complex heterogeneous metabolic disorder characterized by a defect in the function of insulin, is on the rapid rise globally. Sustained hyperglycemia which is a major sign of DM is linked to the generation of reactive oxygen species which promotes adverse complications of the disorder. Traditional herbal treatment of DM is a common practice in Africa and other tropical parts of the world. Vernonia amygdalina (VA), one of the highly researched species in the Asteraceae family, has proven to possess potent antidiabetic properties. Several phytochemicals identified in multiple extracts from VA are purported to be responsible for the antidiabetic potential of the plant. In this review, we discuss the therapeutic potential of VA in diabetes and its associated complications. We appraise the current evidence and further suggest potential areas that could be effectively exploited in future VA research on diabetes.
- Open Access
- 15 November 2023
- Published by Elsevier in Clinical Complementary Medicine and Pharmacology
- Vol. 4 (1)
Therapeutic Benefits of Vernonia amygdalina in the Treatment of Inflammation and Its Associated Diseases
- 15 November 2023
- Published by Elsevier in Clinical Complementary Medicine and Pharmacology
- Vol. 4 (1)
Open AccessTherapeutic Benefits of Vernonia amygdalina in the Treatment of Inflammation and Its Associated Diseases
- Open Access
- 28 March 2023
- Published by IntechOpen
The Link Between Adenoids and Nasopharyngeal Carcinoma
Adenoids, play a significant role in inflammatory response, especially in children. Together with other tissues of the lymphatic system, it fights off infections. In most cases of nasopharyngeal cancer, though rare, other histopathological variants of adenoids are seen. Adenoid hypertrophy is mostly observed, which causes obstruction of the nasopharynx and dysfunction of the Eustachian tube because of the formation of an abnormal tissue mass. Different viral and bacterial pathogens are associated with adenoid hypertrophy, including Epstein-Barr virus (EBV), coronavirus, parainfluenza virus, Mycoplasma pneumoniae, Staphylococcus aureus, and Neisseria gonorrhoeae. Among these, EBV is associated with both adenoid hypertrophy and nasopharyngeal cancer, indicating the effect of EBV on both nasopharyngeal cancer and adenoids. We critically appraise the current evidence and discuss potential link between adenoids and nasopharyngeal carcinoma.
- 28 March 2023
- Published by IntechOpen
Open AccessThe Link Between Adenoids and Nasopharyngeal Carcinoma
Adenoids, play a significant role in inflammatory response, especially in children. Together with other tissues of the lymphatic system, it fights off infections. In most cases of nasopharyngeal cancer, though rare, other histopathological variants of adenoids are seen. Adenoid hypertrophy is mostly observed, which causes obstruction of the nasopharynx and dysfunction of the Eustachian tube because of the formation of an abnormal tissue mass. Different viral and bacterial pathogens are associated with adenoid hypertrophy, including Epstein-Barr virus (EBV), coronavirus, parainfluenza virus, Mycoplasma pneumoniae, Staphylococcus aureus, and Neisseria gonorrhoeae. Among these, EBV is associated with both adenoid hypertrophy and nasopharyngeal cancer, indicating the effect of EBV on both nasopharyngeal cancer and adenoids. We critically appraise the current evidence and discuss potential link between adenoids and nasopharyngeal carcinoma.
- Open Access
- 1 January 2023
- Published by Korean Society of Occupational & Environmental Medicine in Annals of Occupational and Environmental Medicine
- Vol. 35 (1) , e39
Dynamics of pre-shift and post-shift lung function parameters among wood workers in Ghana
Ekman J, et al. Ann Occup Environ Med. 2023 Sep;35:e39. https://doi.org/10.35371/aoem.2023.35.e39
- 1 January 2023
- Published by Korean Society of Occupational & Environmental Medicine in Annals of Occupational and Environmental Medicine
- Vol. 35 (1) , e39
Open AccessDynamics of pre-shift and post-shift lung function parameters among wood workers in Ghana
Ekman J, et al. Ann Occup Environ Med. 2023 Sep;35:e39. https://doi.org/10.35371/aoem.2023.35.e39
- 9 November 2021
- Published by Wiley in International Journal of Developmental Neuroscience
- Vol. 82 (1) , 50-62
Effects of in utero exposure to monosodium glutamate on locomotion, anxiety, depression, memory and KCC2 expression in offspring
In pregnancy, there is a significant risk for developing embryos to be adversely affected by everyday chemicals such as food additives and environmental toxins. In recent times, several studies have documented the detrimental effect of exposure to such chemicals on the behaviour and neurodevelopment of the offspring. This study evaluated the influence of the food additive, monosodium glutamate (MSG), on behaviour and development in mice. Pregnant dams were exposed to MSG 2 or 4 g/kg or distilled water from gestation day 10–20. On delivery, postnatal day 1 (PN 1), 3 pups were sacrificed and whole brain samples assayed for KCC2 expression by western blot. The remaining pups were housed until PN 43 before commencing behavioural assessment. Their weights were measured at birth and at 3 days intervals until PN 42. The impact of prenatal exposure to MSG on baseline exploratory, anxiety and depression behaviours as well as spatial and working memory was assessed. In utero exposure to 4 g/kg MSG significantly reduced exploratory drive and increased depression‐like behaviours but did not exert any significant impact on anxiety‐like behaviours (p < 0.01). Additionally, there was a two‐fold increase in KCC2 expression in both 2 and 4 g/kg MSG‐exposed offspring.Conclusion: This study indicates that, in utero exposure to MSG increases the expression of KCC2 and causes significant effect on locomotion and depression‐like behaviours but only marginally affects memory function.
- 9 November 2021
- Published by Wiley in International Journal of Developmental Neuroscience
- Vol. 82 (1) , 50-62
Effects of in utero exposure to monosodium glutamate on locomotion, anxiety, depression, memory and KCC2 expression in offspring
In pregnancy, there is a significant risk for developing embryos to be adversely affected by everyday chemicals such as food additives and environmental toxins. In recent times, several studies have documented the detrimental effect of exposure to such chemicals on the behaviour and neurodevelopment of the offspring. This study evaluated the influence of the food additive, monosodium glutamate (MSG), on behaviour and development in mice. Pregnant dams were exposed to MSG 2 or 4 g/kg or distilled water from gestation day 10–20. On delivery, postnatal day 1 (PN 1), 3 pups were sacrificed and whole brain samples assayed for KCC2 expression by western blot. The remaining pups were housed until PN 43 before commencing behavioural assessment. Their weights were measured at birth and at 3 days intervals until PN 42. The impact of prenatal exposure to MSG on baseline exploratory, anxiety and depression behaviours as well as spatial and working memory was assessed. In utero exposure to 4 g/kg MSG significantly reduced exploratory drive and increased depression‐like behaviours but did not exert any significant impact on anxiety‐like behaviours (p < 0.01). Additionally, there was a two‐fold increase in KCC2 expression in both 2 and 4 g/kg MSG‐exposed offspring.Conclusion: This study indicates that, in utero exposure to MSG increases the expression of KCC2 and causes significant effect on locomotion and depression‐like behaviours but only marginally affects memory function.